Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement.
about
Advances in understanding and treating ADHDLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesSafety of stimulant treatment in attention deficit hyperactivity disorder: part II.Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory.Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulantsPharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence?Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlatesImpact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis.The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and designRelationship between symptom impairment and treatment outcome in children and adolescents with attention-deficit/hyperactivity disorder: a physician perspectiveImproved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?Managing attention deficit/hyperactivity disorder: unmet needs and future directionsMeditation or Medication? Mindfulness training versus medication in the treatment of childhood ADHD: a randomized controlled trial.Will working memory training generalize to improve off-task behavior in children with attention-deficit/hyperactivity disorder?Effectiveness of a focused, brief psychoeducation program for parents of ADHD children: improvement of medication adherence and symptoms.Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.The NICE ADHD health technology assessment: a review and critiqueSummer treatment programs for youth with ADHDTraumatic dental injuries and attention-deficit/hyperactivity disorder: is there a link?Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia.Global issues related to the impact of untreated attention-deficit/hyperactivity disorder from childhood to young adulthood.Executive Function Training for Children with Attention Deficit Hyperactivity Disorder.Assessment of parents' preferences for the treatment of school-age children with ADHD: a discrete choice experiment.Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.Barriers to evidence-based treatment for children with attention-deficit/hyperactivity disorder.Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD.Influence of methylphenidate on eating in obese men.Children's persistence with methylphenidate therapy: a population-based study.Assessment of adherence measures with different stimulants among children and adolescents.A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial.Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.Beyond the pill: new medication delivery options for ADHD.
P2860
Q24601949-4A48BEB1-E3FD-465C-8498-E5B4C4EEFED6Q26822392-5FF7D768-7DB6-4E45-9473-8566E626C329Q30451303-28C2D93A-D9A4-4222-83F7-ADD8D5987A5DQ33583484-E7089338-C065-4C06-9B10-32736D806234Q33746664-942F09A3-EF75-4B89-977A-82E8D071C566Q34274119-B7E22370-C454-41A1-A7C0-020098937455Q34566730-F5B30C38-D658-4090-A9BF-A73CED024538Q34619814-CF688EE6-FFAF-42C0-99AD-8BEC1C76017FQ35098070-2E866AEA-AEC1-410D-9A63-C48873A9A920Q35123049-9E68F5A6-DC65-410E-A775-9F10DD6BAC8CQ35183156-DCB7B80A-8AA4-4EB5-83D5-90201F4BFC1CQ35575707-6688DBA4-AA43-4D78-AF01-9CD891E54CFCQ36086314-6FCF6EB9-DA75-4C59-A3F3-C3383B8D59B8Q36233139-1B5AFD6D-1E9E-477F-BDF8-0B5EF5D1FE1CQ36306434-B809D9E3-5778-4E01-B6F0-8F8BCF5F0FCCQ36409734-20FDD598-8E85-4705-B73D-F2E33085E6B2Q36491460-C3D519CC-4978-49F3-90A8-4A96DEBDAE99Q36678856-A7489BB5-3ACD-436E-AFA7-0DB4200BDFE1Q36826122-12C87039-2DBB-4544-BC13-EC374ED0B5D1Q37225350-25CB0938-DD4F-4995-88D5-641091DD3F15Q37282163-100D4983-69C4-43DF-AD4A-FA7855EC62C1Q37684136-17654CDA-89B7-4E65-86E9-F1E48B1DDC1BQ37889262-A10514C8-BC5B-46AE-84FF-44D689418874Q38043921-872ECFAE-FADA-4A06-94A9-79342D00CE45Q38233243-08251249-3E84-4A8B-895D-EE36734D70C8Q38418781-9B08757E-E331-4181-BE61-49CFAEFC8427Q40198244-896560B6-6BA2-44A8-8FF5-34822B849EB2Q42113942-8022075C-D16A-459C-BF12-E7B6F152D8CBQ42620075-A9C62F5A-08F4-4DB2-AEDF-334464180A15Q44774930-D18D46BE-4D7D-40B5-ACBC-650276EFDBD3Q45212723-E9A1568B-F250-4A65-B28E-61C6D6972B18Q46592039-0667E9E1-F867-48E1-AAEF-110233A36272Q46863548-3E6B01C3-F672-4D35-85A8-C44E269EF2EFQ47571549-47B9A5B5-05DA-4D23-9103-51D133AC7B3FQ47741544-20300DC1-4F4B-44F0-9093-1BE9E2EDCEFCQ48283852-707F27A8-4C23-4B94-9AE2-B91D3A04493BQ50433156-0B8E2023-99EB-463B-A018-F1029B7C17C1
P2860
Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Compliance with stimulants for ...... nd approaches for improvement.
@en
type
label
Compliance with stimulants for ...... nd approaches for improvement.
@en
prefLabel
Compliance with stimulants for ...... nd approaches for improvement.
@en
P1433
P1476
Compliance with stimulants for ...... nd approaches for improvement.
@en
P2093
James Swanson
P304
P356
10.2165/00023210-200317020-00004
P577
2003-01-01T00:00:00Z
P6179
1028481068